From 1 July 2020, employers in Switzerland with 100 or more employees are obliged to carry out an internal equality pay analysis within one year (Art. 13a, 13c und 13d GlG). This obligation also applies to the following Swiss Roche legal entities:
F. Hoffmann La-Roche AG
Roche Glycart AG
Roche Pharma (Schweiz) AG
Tavero AG
Roche Diagnostics International AG Basel branch Diabetes Care
Roche Diagnostics International AG
Roche Diagnostics (Schweiz) AG
All Roche companies in Switzerland subject to this federal act conducted the equal pay analysis in 2021 in accordance with the Gender Equality Act. The equal pay analyses confirmed that equal pay requirements between women and men are met. As required by the federal act, the equal pay analyses were verified by either a Roche employees’ representation or by a licensed audit firm.
The outcome of the study is in line with the positive results already achieved by Roche prior to the legal obligation as part of the federal voluntary
Employers who can provide evidence of pay equity as they have successfully conducted the compulsory federal equal pay analysis are legally exempt from further analyses (Art. 13a para. 3 GlG). Nevertheless, Roche will voluntarily continue to carry out regular analyses and reviews in the future.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.